Patent · US Active

Recombinant poxvirus vector comprising tetanus toxin fragment C

US9463238B2 · kind B2 · utility

2Cited by

0References

19Claims

0Family size

Assignee

Bavarian Nordic A/S · DK

Inventors

Paul Chaplin · Munich, DE
Robin Steigerwald · Munich, DE

Key dates

Filing date	Nov 30, 2012
Grant date	Oct 11, 2016
Priority date	—
Expiry date	Feb 10, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/70
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a recombinant poxvirus comprising tetanus toxin fragment C for improved immunogenicity of an antigen and related methods and uses. Specifically, the present invention generally relates to genetically engineered (recombinant) poxvirus vectors comprising a tetanus toxin fragment C (TTC) coding sequence operably linked to a bacterial antigenic determinant as well as to uses thereof, e.g., to affect an immune response in a subject.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.